Adaptive Vaccination Protocol™ (AVP™)

An Immune Stabilizing Framework for MCAS, Long COVID, Dysautonomia, and Infection-Associated Chronic Conditions

By: Cynthia Adinig

Introduction

Vaccination remains one of the most important public health interventions in modern medicine, but conventional vaccine administration systems are still largely designed around population-level scheduling rather than individualized physiologic readiness. For most patients, this approach is appropriate and highly effective. However, patients with infection-associated chronic conditions (IACCs), mast cell activation syndromes, dysautonomia, Long COVID, ME/CFS, hypermobility-associated illness, autoimmune, asthma, and environmentally reactive chronic disease may experience immune stimulation differently because their baseline physiology is often already unstable. These patients frequently report exaggerated or prolonged responses to infections, medications, allergens, heat, exertion, environmental exposures, hormonal shifts, and vaccination, suggesting that vaccine tolerability may depend not only on the product itself, but also on the biologic terrain into which the vaccine is introduced (Komaroff and Lipkin, 2021; Klein et al., 2023; Sumantri et al., 2023).

Prior CYNAERA modeling frameworks outlined in The Uncounted: Vaccine Injury Prevalence, Economic Burden, and Reform estimated that 8–12 million Americans may be experiencing chronic health impacts following COVID-19 vaccination, with a substantial portion involving neuroimmune, autonomic, mast-cell-mediated, and post-exertional phenotypes frequently overlapping with infection-associated chronic conditions.

The need for a more adaptive framework is reinforced by the fact that vaccine adverse events are real, documented, and usually rare, but current surveillance systems are not designed to fully capture delayed flare patterns, functional crashes, mast-cell-mediated destabilization, or prolonged symptom worsening in complex chronic illness populations. The National Academies’ 2024 evidence review concluded that mRNA COVID-19 vaccines can cause myocarditis, while CDC vaccine safety monitoring identifies anaphylaxis and myocarditis or pericarditis as serious adverse events following COVID-19 vaccination, with other rare events such as Guillain-Barré syndrome continuing to be monitored (National Academies of Sciences, Engineering, and Medicine, 2024; CDC, 2025). These findings do not support vaccine avoidance. Instead, they support the need for more precise risk stratification, readiness assessment, and adaptive administration pathways for vulnerable patients.

Emerging research on post-vaccination chronic illness further strengthens the case for a more nuanced framework. A descriptive analysis of individuals reporting post-vaccination syndrome found high symptom burden and reduced health status among affected participants (Krumholz et al., 2023). A Yale-led immune profiling study later identified immunologic and antigenic differences in people reporting chronic symptoms after COVID-19 vaccination, including altered immune profiles that may help guide future research (Bhattacharjee et al., 2025). While this literature remains early and should not be overstated, it provides biologic plausibility for the idea that some patients may experience prolonged immune or neuroimmune disruption after vaccination, particularly when vaccination occurs during periods of baseline instability.

The Adaptive Vaccination Protocol™ (AVP™) was developed to address this gap. AVP™ is not an anti-vaccine framework. It is an immune-stabilizing vaccine administration framework for patients whose physiology may require more careful timing, preparation, monitoring, and environmental control. The framework builds on Va-IRI™, the Vaccination Immune Readiness Index, which scores readiness using infection clearance, immune function, inflammation terrain, clotting terrain, antibody landscape, and functional baseline. Va-IRI™ determines whether a patient may be ready for immune stimulation, while AVP™ addresses how vaccination may be timed, supported, administered, and monitored in immune-volatile patients.

AVP™ proposes that safer vaccination in medically complex populations may require attention to five interacting domains: immune readiness, mast cell stability, autonomic stability, environmental load, and hormonal timing. This is especially important for patients with MCAS, Long COVID, dysautonomia, ME/CFS, asthma, and other IACCs because many already experience nonlinear symptom behavior, delayed crashes, and trigger-stacking effects. In this model, vaccination is not treated as an isolated exposure. It is treated as an immune event occurring within a broader terrain shaped by infection history, inflammatory status, environmental exposures, endocrine state, autonomic compensation, and recovery capacity.

Immune Volatility in Infection Associated Chronic Conditions

Infection associated chronic conditions are increasingly recognized as complex multisystem illnesses involving immune dysregulation, autonomic dysfunction, inflammatory persistence, endothelial dysfunction, neurologic symptoms, and impaired recovery signaling. Long COVID research has identified fatigue, post-exertional malaise, cognitive symptoms, and autonomic dysfunction as common features, while immune profiling studies have shown measurable biologic differences between Long COVID patients and controls (Klein et al., 2023). ME/CFS literature similarly describes immune, neurologic, metabolic, and exertion-related abnormalities that can produce prolonged symptom worsening after physiologic stress (Komaroff and Lipkin, 2021).

Many IACC patients do not respond to stressors in a linear or predictable way. A stimulus that is tolerated during a stable baseline may trigger a severe flare during a period of infection recovery, poor sleep, active inflammation, mold exposure, wildfire smoke exposure, menstrual cycle instability, perimenopause, or autonomic strain. This is one of the central reasons AVP™ is needed. Standard vaccine workflows often ask whether a patient has a formal contraindication, but they rarely ask whether the patient is currently physiologically stable enough to tolerate immune stimulation.

Several recurring features appear across many immune-volatile IACC populations:

• Relapsing-remitting symptom behavior with delayed or nonlinear crashes

• Post-exertional symptom amplification following physical, cognitive, inflammatory, or environmental stressors

• Autonomic instability involving heart rate, blood pressure, thermoregulation, and vascular tone

• Mast-cell-mediated inflammatory sensitivity involving histamine release, flushing, GI symptoms, airway symptoms, and neurologic reactivity

• Heightened vulnerability to environmental exposures including wildfire smoke, mold, heat, humidity, pollen, and poor air quality

• Hormone-linked symptom fluctuation associated with menstrual cycling, perimenopause, menopause transition, or endocrine instability

• Reduced recovery reserve following infection, exertion, immune stimulation, or overlapping physiologic stressors

• Delayed recovery trajectories compared with conventional post-viral or inflammatory recovery models

These overlapping features suggest that immune stimulation may be tolerated differently depending on the patient’s current inflammatory terrain, autonomic stability, environmental burden, and recovery capacity at the time of exposure.

Mast cell activation is highly relevant to this problem. Mast cells regulate allergic response, vascular permeability, inflammatory signaling, histamine release, neurologic symptoms, gastrointestinal reactivity, and airway response. Long COVID literature has identified overlap between Long COVID symptom patterns and MCAS-like presentations, while mast cell disorder guidance recognizes that some high-risk patients may require individualized precautions or premedication strategies around vaccination or procedures (Sumantri et al., 2023; Bonadonna et al., 2021). This does not mean all MCAS patients should avoid vaccination. In fact, studies and allergy guidance suggest many mast cell disorder patients can tolerate COVID-19 vaccination, especially when appropriately evaluated and supported (Rama et al., 2022; AAAAI, 2022).

Autonomic dysfunction is another major AVP™ domain. Patients with POTS and dysautonomia may experience exaggerated heart rate changes, blood pressure instability, heat intolerance, dizziness, fatigue, migraine, gastrointestinal symptoms, and post-exertional worsening. Research has identified possible associations between COVID-19 vaccination and new or worsened POTS-related diagnoses, while also showing that SARS-CoV-2 infection carries a greater POTS risk than vaccination (Kwan et al., 2022; Yong, 2023; Bushi et al., 2024). This distinction matters. AVP™ should not frame vaccines as the larger danger compared with infection. It should argue that both infection and vaccination are immune stressors, and vulnerable patients need better protocols to reduce destabilization risk from either exposure.

Immune volatility is also shaped by environmental conditions. Air pollution, wildfire smoke, mold, damp indoor environments, pollen burden, humidity, heat, and storm-front pressure changes can each increase inflammatory or autonomic strain in susceptible patients. Wildfire smoke exposure has systemic health effects involving respiratory, cardiovascular, neurologic, inflammatory, and oxidative stress pathways (Rizzo et al., 2025). Dampness and mold are associated with allergic and respiratory effects, including asthma exacerbation, while CDC/NIOSH recognizes associations between damp indoor spaces and worsening asthma symptoms in people with pre-existing asthma (Mendell et al., 2011; CDC/NIOSH, 2025). For patients whose baseline conditions already involve MCAS, asthma, Long COVID, dysautonomia, or inflammatory reactivity, these exposures may act as immune-load amplifiers.

Hormonal timing adds another overlooked layer. Estrogen and progesterone influence mast cell behavior, allergic inflammation, immune signaling, and symptom expression. Reviews have found that female sex hormones can influence mast cell function and allergic immune responses, with estrogen generally enhancing mast cell reactivity and allergic inflammation in several models (Zierau et al., 2012; Bonds and Midoro-Horiuti, 2013; Gutiérrez-Brito et al., 2025). Menstrual cycle research also suggests COVID-19 vaccination can be associated with small, temporary changes in menstrual cycle length, reinforcing the biologic plausibility that immune stimulation and reproductive endocrine signaling may interact (Gibson et al., 2022; Harvard T.H. Chan School of Public Health, 2024).

Why Standard Vaccine Administration Frameworks Can Fail Immune Volatile Patients

Standard vaccine administration frameworks are designed for safety, scalability, efficiency, and public health reach. These goals are appropriate at the population level, but they can leave medically complex patients without practical guidance. A typical vaccine workflow may screen for severe allergic reaction history, acute illness, prior contraindications, and immediate adverse event risk, but it usually does not evaluate environmental load, hormonal phase, MCAS status, dysautonomia severity, recent post-exertional malaise, mold exposure, wildfire smoke exposure, HRV changes, recent infection recovery, or symptom baseline stability. For immune-volatile patients, those missing variables may be clinically meaningful.

This gap is especially important because serious vaccine adverse events are generally rare, but rare does not mean irrelevant. The National Academies’ adverse effects review and CDC safety monitoring provide a credible foundation for discussing vaccine-related harm without overstating it. CDC identifies anaphylaxis and myocarditis or pericarditis as serious adverse events following COVID-19 vaccination and monitors other rare events such as Guillain-Barré syndrome (CDC, 2025). The National Academies concluded that the Pfizer-BioNTech and Moderna mRNA vaccines can cause myocarditis, while evidence suggested they do not cause several other outcomes, including infertility, Guillain-Barré syndrome, Bell’s palsy, thrombosis with thrombocytopenia syndrome, or myocardial infarction (National Academies of Sciences, Engineering, and Medicine, 2024). This balanced evidence base allows AVP™ to occupy the responsible middle lane: vaccine adverse events exist, but the answer is adaptive safety infrastructure, not blanket fear.

The problem is that current systems often treat the absence of a recognized contraindication as equivalent to readiness. In immune-volatile patients, that assumption may fail. A patient may not have a formal contraindication and may still be in a high-risk flare state because of active MCAS symptoms, poor sleep, unstable resting heart rate, recent infection, high inflammatory burden, mold exposure, poor air quality, heat stress, or a major storm front. Va-IRI™ addresses part of this gap by scoring readiness across immune, inflammatory, clotting, antibody, infection-clearance, and functional domains. AVP™ extends this logic into the practical administration pathway by asking how to prepare, when to schedule, what to avoid, what to monitor, and when to defer.

Environmental timing is one of the clearest examples of a missing vaccine safety variable. Air pollution and PM2.5 exposure are linked to lung inflammation, allergic disease exacerbation, cardiovascular effects, and systemic inflammatory pathways (Tuazon et al., 2022; Rajagopalan et al., 2018). PM2.5 has also been shown in experimental literature to enhance mast cell activation pathways, which is directly relevant for MCAS and allergic inflammatory phenotypes (Jin et al., 2019; Wang et al., 2021). Wildfire smoke introduces an even more concentrated exposure problem because it contains fine particulate matter and toxic gases that can affect respiratory, cardiovascular, neurologic, inflammatory, and oxidative stress pathways (Rizzo et al., 2025).

Mold and damp indoor environments should also be treated as administration-relevant variables. The literature consistently links dampness or mold with allergic and respiratory effects, and CDC/NIOSH recognizes that damp indoor spaces can worsen asthma symptoms and are associated with new-onset asthma (Mendell et al., 2011; CDC/NIOSH, 2025). For a patient with MCAS, asthma, Long COVID, or dysautonomia, receiving a vaccine during active mold exposure or remediation may create a cumulative trigger load. AVP™ should therefore recommend that clinicians and patients consider whether the patient is in an active mold flare, undergoing remediation, sleeping in a damp environment, or experiencing increased respiratory symptoms before scheduling vaccination.

Weather instability and barometric pressure changes are less established than AQI or mold, but they remain clinically relevant for a subset of patients with migraine, dysautonomia, MCAS, and Long COVID. Migraine literature reports associations between headache occurrence and weather variables such as barometric pressure, humidity, rainfall, and wind, though findings are not always consistent (Denney et al., 2024; Katsuki et al., 2023). AVP™ should frame storm fronts and barometric shifts as patient-specific risk modifiers rather than universal contraindications. In practical terms, patients who consistently flare during storm fronts may benefit from avoiding vaccination immediately before or during major pressure shifts when scheduling flexibility exists.

Hormonal timing is another major limitation in standard workflows. Menstrual cycle phase, perimenopause, menopause transition, postpartum state, endometriosis, PMDD, mast cell reactivity, and hormone therapy status are rarely considered in vaccination guidance. Yet sex hormones influence mast cell function, allergic inflammation, and immune regulation (Zierau et al., 2012; Bonds and Midoro-Horiuti, 2013; Gutiérrez-Brito et al., 2025). COVID-19 vaccination has also been associated with small, temporary menstrual cycle length changes in large cycle-tracking studies, suggesting that immune activation and reproductive endocrine signaling can interact in measurable ways (Gibson et al., 2022; Harvard T.H. Chan School of Public Health, 2024). AVP™ does not need to claim that one cycle phase is universally safe or unsafe. It only needs to argue that patients with known hormone-linked flares should be allowed to schedule vaccination during their most stable personal window.

Standard Vaccine Workflow vs. AVP™ Adaptive Workflow

Standard Vaccine Workflow	AVP™ Adaptive Workflow
Screens for formal contraindications	Screens for readiness, instability, and flare risk
Focuses on immediate allergic reaction risk	Includes delayed flare, PEM, MCAS, and dysautonomia risk
Uses calendar-based scheduling	Uses terrain-based timing
Rarely considers AQI, mold, wildfire smoke, or storm fronts	Treats environmental load as a modifiable risk factor
Rarely considers menstrual cycle, perimenopause, or hormone-linked flares	Treats hormonal stability as part of immune readiness
Assumes recovery follows standard reactogenicity windows	Monitors for delayed crashes and prolonged symptom activation
Prioritizes population-scale efficiency	Adds individualized safeguards for immune-volatile patients
May unintentionally increase distrust when symptoms are dismissed	Builds trust by validating complexity while preserving vaccine access

The Adaptive Vaccination Protocol™ Model

The Adaptive Vaccination Protocol™ is an immune-stabilizing administration framework designed for patients whose vaccine tolerance may be influenced by immune readiness, mast cell activity, autonomic stability, environmental exposure, hormonal timing, and post-vaccination recovery capacity. The protocol is intended to support safer access to vaccination for medically complex patients, not to discourage vaccination. Its central premise is that immune stimulation may be better tolerated when avoidable physiologic stressors are reduced before, during, and after administration.

Phenotype-Based Stabilization Mapping

To support phenotype-responsive implementation, AVP™ adapts the model-derived phenotype categories described in The Uncounted: Vaccine Injury Prevalence, Economic Burden, and Reform and translates them into stabilization priorities for vaccine administration. In that prior framework, chronic post-vaccination presentations were modeled across ME/CFS-like, dysautonomia, MCAS-hyperreactive, neuropathic, autoimmune, vestibular, gastrointestinal, vascular, dermatologic, and persistent cardiac phenotypes (Adinig, 2025). AVP™ does not treat these categories as fixed diagnostic labels. Instead, it uses them as protocol-relevant risk patterns that may guide preparation, timing, monitoring, and recovery support.

Primary Phenotype	Modeled Risk Share	Supporting Literature	AVP™ Stabilization Priority
ME/CFS-like, PEM-dominant	24%	Post-exertional symptom exacerbation and impaired recovery are central to ME/CFS and overlap with Long COVID (NICE, 2021; Komaroff and Lipkin, 2021; Davis et al., 2023).	Pacing, rest window, workload reduction, delayed-flare monitoring
POTS / dysautonomia	20%	POTS and autonomic dysfunction involve HR/BP instability, orthostatic intolerance, dizziness, fatigue, and heat sensitivity (Sheldon et al., 2015; Kwan et al., 2022; Yong, 2023).	Hydration, electrolytes, reclined positioning, HR/BP tracking
MCAS hyperreactivity	17%	Mast cell activation overlaps with Long COVID symptoms and may require individualized vaccination precautions in selected high-risk patients (Sumantri et al., 2023; Bonadonna et al., 2021; Rama et al., 2022).	Clinician-guided H1/H2 planning, rescue meds, trigger reduction
Small fiber neuropathy / neuropathic pain	12%	Small fiber neuropathy and neuropathic symptoms have been reported in Long COVID and dysautonomia-associated presentations (Oaklander et al., 2022; Abrams et al., 2020).	Neurologic symptom tracking, avoid trigger stacking, sensory flare monitoring
Autoimmune disease, new-onset or flare-prone	7%	Immune activation, autoantibodies, and inflammatory dysregulation have been described in COVID-related immune disturbance and post-vaccination chronic illness research (Wang et al., 2021; Krumholz et al., 2023; Bhattacharjee et al., 2025).	Baseline stability check, inflammatory marker review if available
Tinnitus / vestibular phenotype	6%	Vestibular symptoms, migraine overlap, and neurologic sensitivity are reported across Long COVID and post-viral syndromes (Davis et al., 2023; Denney et al., 2024).	Avoid storm-front windows, monitor migraine and vestibular symptoms
GI dysmotility / IBS-like phenotype	5%	GI dysmotility and mast-cell-linked GI reactivity are common in dysautonomia, MCAS, and Long COVID symptom clusters (Sumantri et al., 2023; Davis et al., 2023).	Food stability, hydration, medication tolerance review
Vascular / coagulation dysregulation	4%	Endothelial dysfunction, clotting abnormalities, and vascular inflammation are reported in Long COVID literature (Su et al., 2022; Pretorius et al., 2021).	Clinician review, avoid active flare, consider Va-IRI clotting terrain
Dermatologic urticaria / angioedema	3%	Urticaria, flushing, angioedema, and allergic-type reactions are consistent with mast-cell-mediated inflammatory presentations (Bonadonna et al., 2021; Rama et al., 2022).	Allergy planning, rescue meds, extended observation if indicated
Myocarditis / pericarditis, persistent sequelae	2%	Myocarditis is a recognized rare serious adverse event after mRNA vaccination and requires medical evaluation and risk-specific guidance (National Academies, 2024; CDC, 2025).	Medical clearance, avoid high-risk timing, urgent symptom plan

This phenotype map allows AVP™ to bridge modeled risk distribution with practical stabilization planning. The goal is not to assign causal certainty to every post-vaccination symptom pattern, but to identify which physiologic systems may require added support when a patient presents with immune volatility, autonomic instability, mast-cell reactivity, inflammatory activation, delayed recovery, or prior post-vaccination deterioration. In this way, AVP™ converts broad surveillance and modeling concerns into patient-centered administration logic that can be tested prospectively.

AVP™ organizes vaccine planning into four operational phases: readiness confirmation, stabilization preparation, adaptive administration, and post-vaccination monitoring. Readiness confirmation determines whether vaccination should proceed, be delayed, or require additional medical review. This phase can incorporate Va-IRI™ scoring, current infection status, recent flare history, medication tolerance, autonomic baseline, symptom burden, and clinician judgment. Active infection, unstable asthma, uncontrolled anaphylaxis risk, severe acute flare, or recent major destabilization should prompt deferral or specialist review when clinically appropriate.

Stabilization preparation focuses on reducing preventable trigger load before vaccination. In MCAS or mast-cell-disorder patients, this may include clinician-approved H1/H2 support, mast cell stabilizer review, rescue medication planning, and avoidance of known triggers. The literature supports careful individualized management rather than universal premedication. Allergy guidance has cautioned against routine H1-antihistamine or systemic corticosteroid premedication for the general population to prevent anaphylaxis, while mast cell disorder literature recognizes that selected high-risk patients may receive premedication as part of specialist-guided care (Greenhawt et al., 2023; Bonadonna et al., 2021; Rama et al., 2022). This distinction is important because AVP™ should not be written like generic advice. It should be written as a risk-adapted clinical support model.

Adaptive administration includes practical modifications that may improve tolerability in immune-volatile patients. These may include scheduling during a stable baseline, avoiding vaccination immediately after exertional crashes, providing extended observation for patients with prior reactions, using supine or reclined positioning for POTS-prone patients, ensuring hydration and electrolyte support when appropriate, avoiding known environmental triggers before and after vaccination, and planning access to rescue medications. Dose splitting or fractional dosing should be treated as a research or specialist-supervised consideration only, not as a routine recommendation, because vaccine formulation, immunogenicity, labeling, and pharmacy handling requirements vary by product.

Environmental timing should be formalized as a core AVP™ domain. A green vaccination window would include AQI below 50, no wildfire smoke exposure, no active mold flare or remediation exposure, stable barometric conditions, low personal allergen burden, stable indoor air quality, and no major heat or storm event. A yellow window would include AQI 51 to 100, moderate pollen, mild humidity or pressure changes, minor symptom instability, or manageable environmental stressors. A red window would include AQI above 100, wildfire smoke, active mold exposure, flooding-related microbial exposure, major storm fronts, rapid barometric drops, heat emergencies, asthma flare, MCAS flare, or significant dysautonomia destabilization. In red windows, deferral should be considered when clinically reasonable.

Hormonal timing should be handled as a personalized stability variable rather than a rigid universal rule. For menstruating patients with predictable hormone-linked flares, AVP™ may recommend avoiding historically unstable windows such as severe menstrual flares, late luteal MCAS worsening, migraine-prone phases, or perimenopausal volatility when scheduling flexibility exists. For some patients, early or mid-follicular timing may be better tolerated, but the paper should present this as a patient-specific hypothesis requiring validation rather than a settled rule. This keeps the claim scientifically defensible while still naming the missing variable.

Post-vaccination monitoring should continue for at least several days and longer in patients with delayed crash patterns. Monitoring may include heart rate, blood pressure, temperature, oxygen saturation when relevant, HRV trends, sleep disruption, PEM symptoms, allergic symptoms, neurologic symptoms, GI reactivity, migraine, chest symptoms, and environmental exposure changes. Symptom tracking should be designed to distinguish expected short-term reactogenicity from prolonged flare behavior. This is where AVP™ can integrate with SymCas™ for flare sequencing and VitalGuard™ for environmental overlay logic. The AVP™ model therefore reframes vaccination in immune-volatile patients as a coordinated process rather than a single appointment. The clinical goal is not to eliminate all risk, which is impossible. The goal is to reduce avoidable destabilization, improve patient trust, preserve vaccine access, and create a structured framework for future prospective research. 

Environmental Timing and Exposure Burden in Immune-Volatile Patients

Environmental exposure burden represents one of the most overlooked variables in vaccine administration for chronically ill populations. Patients with MCAS, asthma, Long COVID, dysautonomia, migraine disorders, ME/CFS, and environmentally reactive inflammatory conditions frequently report worsening symptoms during periods of elevated air pollution, wildfire smoke exposure, mold exposure, pollen surges, extreme heat, humidity shifts, flooding events, and rapid barometric pressure changes. Despite this, conventional vaccine administration guidance rarely incorporates environmental conditions into scheduling or stabilization decisions. AVP™ proposes that environmental load should be considered a clinically relevant modifier of immune tolerance and recovery capacity in vulnerable populations.

This omission reflects a broader limitation in modern medicine, where environmental exposures are often treated as background variables rather than active physiologic stressors. Yet mounting evidence demonstrates that air pollution, particulate matter, microbial exposure, and atmospheric instability can influence inflammatory signaling, vascular function, autonomic regulation, oxidative stress, allergic response, and immune behavior (Rajagopalan et al., 2018; Tuazon et al., 2022). For patients whose baseline conditions already involve mast cell activation, autonomic dysfunction, endothelial instability, or chronic inflammatory activation, these exposures may reduce recovery reserve and increase vulnerability to additional physiologic stressors, including immune stimulation.

AVP™ therefore conceptualizes vaccination not as an isolated event, but as an immune challenge occurring within a broader physiologic terrain shaped by environmental conditions, autonomic stability, inflammatory burden, endocrine state, and recovery capacity. In this framework, environmental timing becomes part of adaptive vaccine support rather than a peripheral consideration.

Air Pollution, PM2.5, and Wildfire Smoke as Immune Stressors

Air pollution and PM2.5 exposure are increasingly recognized as systemic inflammatory stressors rather than isolated respiratory irritants. Fine particulate matter exposure has been associated with oxidative stress, endothelial dysfunction, cardiovascular disease, asthma exacerbation, immune dysregulation, and inflammatory activation (Rajagopalan et al., 2018; Tuazon et al., 2022). Experimental studies have also demonstrated that PM2.5 can enhance mast cell activation pathways and inflammatory signaling, potentially increasing histamine release and allergic reactivity in susceptible individuals (Jin et al., 2019; Wang et al., 2021).

For patients with MCAS, asthma, Long COVID, and dysautonomia, these inflammatory effects may have broader systemic implications. Many patients report worsening tachycardia, migraine activity, dizziness, fatigue, airway irritation, flushing, chest tightness, and post-exertional symptom amplification during periods of elevated AQI. In immune-volatile populations, vaccination during periods of significant particulate exposure may therefore create additive inflammatory burden rather than isolated immune activation.

Wildfire smoke exposure may be particularly relevant within the AVP™ framework because it combines fine particulate matter with toxic gases, volatile organic compounds, oxidative stress pathways, and respiratory irritation. Reviews of wildfire smoke exposure have linked these events to respiratory illness, cardiovascular strain, inflammatory activation, neurologic symptoms, and worsening chronic disease burden (Cascio, 2018; Rizzo et al., 2025). Patients with asthma, MCAS, dysautonomia, and Long COVID may therefore experience reduced physiologic stability during wildfire events even before immune stimulation occurs.

Although direct studies evaluating wildfire smoke and vaccine tolerability are currently limited, AVP™ proposes that concurrent inflammatory stressors may alter baseline recovery capacity in susceptible individuals. In this model, AQI conditions become clinically relevant timing variables rather than unrelated environmental observations.

Mold Exposure, Indoor Air Quality, and Chronic Inflammatory Burden

Mold exposure and indoor air quality instability represent another important yet underrecognized factor within immune-volatile populations. A substantial body of literature has associated dampness and mold exposure with respiratory symptoms, allergic disease, asthma exacerbation, inflammatory airway activation, and reduced respiratory health outcomes (Mendell et al., 2011). CDC and NIOSH guidance similarly recognizes associations between damp indoor spaces, mold exposure, and worsening asthma symptoms in sensitized individuals (CDC/NIOSH, 2025).

Patients with MCAS, asthma, environmental intolerance syndromes, dysautonomia, and Long COVID frequently describe heightened symptom activity during periods of mold exposure, water damage, remediation activity, or severe indoor air quality deterioration. Symptoms may include airway inflammation, tachycardia, fatigue, flushing, migraine, sleep disruption, neurologic symptoms, mast cell activation, and post-exertional worsening. In some cases, patients may already be operating within a heightened inflammatory state before vaccination occurs.

Remediation periods may be particularly destabilizing because they can temporarily increase exposure to airborne particulates, microbial fragments, volatile compounds, and inflammatory triggers. Patients undergoing active remediation or living in water-damaged environments may therefore have reduced physiologic reserve during periods of immune stimulation. AVP™ recommends that clinicians and patients consider recent flooding events, active mold exposure, indoor air quality deterioration, or remediation-related symptom worsening when evaluating vaccine timing in highly sensitive individuals.

Importantly, AVP™ does not argue that mold exposure directly causes vaccine reactions. Instead, the framework proposes that chronic inflammatory burden and environmental immune activation may influence overall recovery capacity in susceptible patients. In this model, indoor environmental conditions become part of a broader terrain-based understanding of immune stability.

Weather Instability, Barometric Pressure, and Autonomic Sensitivity

Weather instability and atmospheric pressure changes may also influence physiologic stability in subsets of chronically ill patients. Migraine literature has documented associations between headache activity and variables such as barometric pressure shifts, humidity changes, rainfall, temperature fluctuations, and storm-front activity, although findings remain heterogeneous across studies (Denney et al., 2024; Katsuki et al., 2023). Patients with dysautonomia, MCAS, Long COVID, and neurologic sensitivity syndromes frequently report similar weather-linked symptom fluctuations involving tachycardia, dizziness, fatigue, migraine, joint pain, flushing, sleep disruption, and autonomic instability.

These effects may reflect interactions between atmospheric conditions, vascular tone, autonomic compensation, inflammatory signaling, and neurologic sensitivity. Rapid pressure shifts may place additional strain on already unstable autonomic systems, particularly in patients with impaired vascular regulation or chronic inflammatory activation. Heat and humidity may further exacerbate dysautonomia by increasing vasodilation, dehydration risk, cardiovascular strain, and orthostatic intolerance.

The AVP™ framework does not treat weather sensitivity as a universal mechanism or formal contraindication. Rather, it recognizes that some patients consistently experience symptom destabilization during major storm fronts, pressure changes, or heat events. In these individuals, vaccination during periods of known physiologic instability may increase the likelihood of cumulative stress burden and impaired recovery.

As with other environmental variables, AVP™ frames atmospheric instability as a patient-specific modifier of immune tolerance rather than a deterministic predictor of vaccine outcome. This distinction is important because it preserves scientific caution while still acknowledging patterns repeatedly observed in clinically complex populations.

Environmental Trigger Stacking and Reduced Recovery Capacity

One of the central concepts underlying AVP™ is environmental trigger stacking. Immune-volatile patients often do not respond to physiologic stressors in isolation. Instead, symptom destabilization may emerge when multiple inflammatory, autonomic, environmental, hormonal, or exertional stressors occur simultaneously or in rapid succession. A patient may tolerate a vaccine during one physiologic window but experience prolonged flare behavior during another depending on cumulative stress burden at the time of administration.

For example, vaccination occurring during wildfire smoke exposure, active mold remediation, severe insomnia, menstrual instability, post-exertional malaise, poor AQI conditions, or major storm-front activity may place immune-fragile patients under significantly greater physiologic strain than vaccination occurring during a stable recovery window. In this framework, the problem is not necessarily the vaccine itself, but the interaction between immune stimulation and reduced recovery reserve.

This concept aligns with broader observations in Long COVID, ME/CFS, MCAS, and dysautonomia populations, where symptom escalation is often nonlinear and cumulative rather than proportional to a single trigger. Patients frequently report delayed crashes occurring after overlapping stressors involving infection, heat exposure, allergens, exertion, emotional stress, poor sleep, or environmental inflammation. AVP™ extends this terrain-based logic into vaccine administration by proposing that cumulative physiologic burden may meaningfully influence tolerability and recovery trajectories.

Importantly, environmental trigger stacking should not be interpreted as evidence that vaccination is inherently unsafe in chronically ill populations. Rather, AVP™ suggests that adaptive timing and stabilization strategies may help reduce avoidable inflammatory amplification in susceptible individuals. In this model, environmental awareness becomes part of risk reduction rather than fear-based avoidance.

Environmental Readiness Windows in the AVP™ Framework

To operationalize environmental timing within adaptive vaccine planning, AVP™ introduces environmental readiness windows designed to help identify periods of relative physiologic stability versus periods of elevated inflammatory burden. These windows are not intended to function as rigid rules or universal contraindications. Instead, they provide a structured framework for integrating environmental conditions into individualized vaccine support decisions for immune-volatile patients.

Green windows represent periods of relative environmental stability. These periods may include AQI below 50, absence of wildfire smoke exposure, stable indoor air quality, no active mold exposure or remediation, low personal allergen burden, stable weather conditions, and manageable baseline symptom activity. Patients vaccinated during green windows may have greater recovery reserve and reduced cumulative inflammatory burden at the time of immune stimulation.

Yellow windows represent moderate environmental stress conditions that may still be manageable depending on the patient’s baseline stability and support measures. These conditions may include AQI between 51 and 100, moderate pollen burden, mild humidity or pressure shifts, manageable environmental symptoms, or temporary increases in autonomic activity. In yellow windows, additional stabilization strategies and post-vaccination monitoring may be appropriate.

Red windows represent periods of substantial environmental instability or inflammatory stress. These periods may include AQI above 100, wildfire smoke exposure, severe heat events, flooding-related microbial exposure, active mold remediation, major storm fronts, rapid barometric pressure drops, severe allergen exposure, or significant environmentally triggered symptom escalation. During red windows, AVP™ recommends considering temporary deferral when clinically reasonable, particularly in highly reactive or medically unstable patients.

The purpose of environmental readiness windows is not to eliminate all risk, which is impossible. Rather, the framework attempts to reduce avoidable trigger stacking and preserve recovery capacity in populations already living with chronic physiologic instability.

Hormonal Timing, Mast Cell Biology, and Vaccine Tolerability

Hormonal signaling represents another major physiologic variable largely absent from conventional vaccine administration frameworks. Estrogen, progesterone, cortisol, and other endocrine pathways influence immune behavior, inflammatory signaling, mast cell activity, vascular tone, autonomic regulation, and symptom expression across numerous chronic illnesses. Patients with MCAS, migraine disorders, autoimmune disease, dysautonomia, PMDD, endometriosis, Long COVID, and ME/CFS frequently report symptom fluctuations associated with menstrual cycle phase, ovulation, progesterone withdrawal, perimenopause, menopause transition, postpartum states, and hormone therapy changes. Despite this, vaccine timing recommendations rarely incorporate hormonal stability or known cycle-linked flare windows.

Emerging literature supports biologic plausibility for hormone-immune interaction in allergic and inflammatory disease. Estrogen has been shown to influence mast cell maturation, degranulation, cytokine production, and allergic inflammatory response in several experimental and clinical models (Zierau et al., 2012; Bonds and Midoro-Horiuti, 2013). Reviews have suggested that female sex hormones may contribute to differences in allergic disease prevalence, mast cell activity, and immune signaling across the lifespan (Gutiérrez-Brito et al., 2025). Progesterone withdrawal has also been associated with inflammatory symptom worsening in some patients, particularly those with migraine disorders, PMDD, mast cell instability, and autoimmune symptom cycling.

These interactions may be particularly important in MCAS and dysautonomia populations. Mast cells contain estrogen and progesterone receptors and may respond dynamically to hormonal fluctuations (Zierau et al., 2012). Patients frequently describe increased histamine symptoms, tachycardia, migraine activity, flushing, gastrointestinal symptoms, fatigue, and inflammatory flares during late luteal phases or menstruation. Similarly, autonomic symptoms in POTS and dysautonomia may worsen during hormonal transitions due to changes in vascular tone, fluid regulation, inflammatory signaling, and stress hormone interaction. These observations suggest that vaccine tolerability may vary depending on underlying hormonal terrain at the time of administration.

COVID-19 vaccination studies further reinforce the existence of immune-endocrine interaction. Large menstrual cycle tracking studies identified small but measurable temporary changes in cycle length following vaccination, supporting the idea that immune stimulation and reproductive endocrine signaling can influence one another (Gibson et al., 2022; Edelman et al., 2022). Although these changes were generally transient and not considered dangerous, the findings demonstrate that vaccination can interact with hormonal physiology in measurable ways. This is particularly relevant for chronically ill patients whose symptom burden is already tightly linked to endocrine fluctuation. (nejm.org)

AVP™ therefore proposes that hormonal timing should be considered a stabilization variable rather than an afterthought. The framework does not claim that one menstrual phase is universally safe or unsafe for vaccination. Instead, it recommends that patients with known hormone-linked flare patterns may benefit from scheduling vaccination during their most stable personal physiologic window whenever flexibility exists. For some patients, early or mid-follicular phases may be associated with lower symptom burden and improved stability, while others may tolerate different windows better depending on their underlying disease patterns and hormonal status.

Perimenopause deserves particular attention within this framework because it is characterized by fluctuating estrogen levels, autonomic instability, sleep disruption, inflammatory shifts, and altered mast cell behavior. Patients with Long COVID, MCAS, dysautonomia, and autoimmune disease frequently report worsening symptom instability during perimenopause, including heightened sensitivity to stressors that were previously tolerated. In these populations, vaccination during periods of active hormonal volatility may increase the likelihood of destabilization, prolonged flare behavior, or impaired recovery.

Hormonal Timing and Immune Volatility in AVP™

Hormonal State or Phase	Potential Immune and Autonomic Effects	AVP™ Considerations
Early to Mid-Follicular Phase	Rising estrogen with relatively lower inflammatory instability in some patients	May represent a more stable vaccination window for select patients
Ovulation Window	Histamine and mast cell activity may increase in sensitive individuals	Monitor for migraine, flushing, tachycardia, or MCAS escalation
Late Luteal Phase	Progesterone withdrawal may increase inflammatory and mast cell reactivity	Consider avoiding vaccination during known flare-prone windows
Menstruation	Fluid shifts, autonomic instability, cramping, migraine, and fatigue may worsen	Evaluate hydration status, autonomic baseline, and symptom burden
Perimenopause	Hormonal fluctuation may destabilize mast cell behavior, sleep, and autonomic regulation	Increased monitoring and individualized timing may be beneficial
Menopause Transition	Altered estrogen signaling and inflammatory changes may affect symptom patterns	Assess baseline stability and environmental stress load
Hormone Therapy Changes	Rapid endocrine shifts may temporarily alter immune and autonomic tolerance	Avoid stacking vaccination with recent major hormone adjustments when possible
PMDD or Hormone-Linked MCAS	Predictable inflammatory and neurologic flare patterns may occur cyclically	Use patient-specific symptom history to identify safer administration windows
Postpartum State	Immune and endocrine rebound activity may alter inflammatory behavior	Consider additional stabilization and recovery monitoring
Surgical Menopause	Sudden endocrine disruption may increase autonomic and inflammatory instability	Delay non-urgent vaccination during acute destabilization periods when clinically appropriate

AVP™ therefore recommends incorporating patient-specific hormonal awareness into vaccine planning where relevant. This may include avoiding historically severe flare windows, tracking symptom patterns across menstrual cycles, accounting for recent hormone therapy changes, and recognizing perimenopausal instability as a meaningful physiologic variable. Hormonal timing should not replace evidence-based vaccination guidance, but it may provide an additional stabilization tool for patients with known endocrine-linked symptom cycling.

Adaptive Administration and Immune Stabilization Strategies

The Adaptive Vaccination Protocol™ proposes that vaccine administration in immune-volatile patients should function as a stabilization process rather than a single isolated event. In conventional settings, vaccination is often treated as a routine encounter requiring minimal physiologic preparation beyond screening for contraindications. However, patients with MCAS, Long COVID, dysautonomia, asthma, ME/CFS, autoimmune disease, and environmentally reactive illness may require additional support before, during, and after immune stimulation in order to reduce avoidable destabilization and improve recovery capacity.

This distinction is supported by the broader literature showing that Long COVID and ME/CFS involve immune, autonomic, inflammatory, neurologic, and exertion-linked abnormalities that can alter recovery after physiologic stressors (Komaroff and Lipkin, 2021; Klein et al., 2023; Davis et al., 2023). It is also consistent with the 2021 NICE ME/CFS guideline, which recognizes post-exertional symptom exacerbation as central to ME/CFS and cautions against approaches that

push patients beyond their energy limits (NICE, 2021).

Pre-Vaccination Stabilization and Readiness Assessment

The stabilization phase begins several days before vaccination whenever possible. AVP™ recommends assessing recent symptom behavior, sleep quality, hydration status, medication tolerance, environmental exposures, autonomic stability, and flare activity before proceeding. Patients experiencing active infection, severe mast cell activation, major post-exertional crashes, uncontrolled asthma, recent anaphylaxis, severe insomnia, wildfire smoke exposure, mold remediation exposure, or significant autonomic instability may benefit from temporary deferral until baseline stability improves. This approach aligns with the broader Va-IRI™ principle that immune stimulation should ideally occur during periods of relative physiologic steadiness rather than active destabilization.

The rationale for readiness assessment is strengthened by evidence that immune-volatile conditions do not behave as static diagnoses. Long COVID studies have identified measurable immune differences, including altered immune cell populations and inflammatory signaling, while ME/CFS literature emphasizes symptom fluctuation, exertion intolerance, and impaired recovery after stress (Klein et al., 2023; Komaroff and Lipkin, 2021). AVP™ therefore treats “readiness” as a dynamic state rather than a fixed label. That makes the framework compatible with Va-IRI™, which scores infection clearance, immune function, inflammatory terrain, clotting terrain, antibody landscape, and functional baseline before immune stimulation.

Hydration, Electrolytes, and Autonomic Support

Hydration and autonomic support are foundational AVP™ components, particularly for patients with POTS and dysautonomia. Increased fluid intake, electrolyte support, compression garments where appropriate, and avoidance of dehydration may help reduce tachycardia, dizziness, presyncope, and orthostatic symptom worsening surrounding vaccination. Patients with severe orthostatic intolerance may also benefit from supine or reclined positioning during and after injection, as well as extended observation periods before discharge.

This recommendation is consistent with established dysautonomia management principles. The 2015 Heart Rhythm Society expert consensus statement describes nonpharmacologic POTS management strategies including increased fluid and salt intake, compression garments, and avoidance of exacerbating factors (Sheldon et al., 2015). Major clinical resources similarly describe POTS as a disorder of autonomic regulation involving heart rate, blood pressure, dizziness, fatigue, and orthostatic intolerance, with hydration, salt, and compression commonly used as supportive measures (Cleveland Clinic, 2022; Johns Hopkins Medicine, 2026).

Mast Cell Stabilization and Premedication Considerations

Mast cell stabilization strategies should be individualized and clinician-guided. The literature does not support universal premedication for the general population, and allergy societies have cautioned against routine antihistamine or corticosteroid premedication solely for prevention of severe allergic reactions in otherwise low-risk individuals (Greenhawt et al., 2023). However, mast cell disorder literature recognizes that selected high-risk patients may receive individualized stabilization approaches, including H1 blockers, H2 blockers, mast cell stabilizers, rescue medication planning, or prolonged observation depending on clinical history (Bonadonna et al., 2021; Rama et al., 2022; Nicola et al., 2024). AVP™ therefore frames premedication not as a universal recommendation, but as a specialist-guided adaptive strategy for vulnerable patients with known mast-cell-mediated reactivity.

This nuance is essential. Studies and expert recommendations generally support COVID-19 vaccination in patients with mast cell disorders while also recognizing that selected patients may require precautions, risk assessment, observation, and premedication based on personal history. Bonadonna et al. recommended broad COVID-19 vaccination access for mastocytosis patients while considering safety measures such as premedication and post-vaccination observation according to individual risk. Rama et al. reported that COVID-19 vaccination appeared safe among patients with clonal mast cell disorders, including patients with prior anaphylaxis. Nicola et al. also notes expert recommendations involving H1 antihistamine premedication in mastocytosis contexts.

Environmental Control During the Peri-Vaccination Window

Environmental control measures are another central AVP™ feature. Patients with asthma, MCAS, Long COVID, or environmental sensitivity may benefit from minimizing additional inflammatory exposures during the peri-vaccination period. This may include avoiding outdoor exertion during poor AQI conditions, using HEPA filtration indoors, limiting wildfire smoke exposure, reducing pollen exposure when relevant, masking during high particulate events, and avoiding mold-contaminated environments before and after vaccination. The goal is not to create a sterile environment, but to reduce cumulative inflammatory load during a period of intentional immune activation.

The scientific basis for this recommendation comes from evidence that environmental exposures can act as systemic inflammatory stressors. PM2.5 and air pollution are associated with oxidative stress, endothelial dysfunction, asthma exacerbation, cardiovascular effects, and immune-mediated respiratory inflammation (Rajagopalan et al., 2018; Tuazon et al., 2022). Mold and dampness have been associated with respiratory and allergic health effects, including asthma exacerbation (Mendell et al., 2011). Wildfire smoke exposure has also been linked to respiratory, cardiovascular, inflammatory, neurologic, and oxidative stress pathways (Cascio, 2018; Rizzo et al., 2025). AVP™ does not claim these exposures cause vaccine reactions directly; it argues that they may reduce recovery reserve when layered onto immune stimulation.

Modeling Example: Same Patient, Same Vaccine, Different Timing Window

Patient profile: 42-year-old woman in Richmond, Virginia. She works as a public school counselor, has Long COVID, MCAS, POTS, asthma, and hormone-linked migraine flares. She has a prior history of delayed post-exertional crashes after infections and immune stimulation.

Month Window	Patient Terrain	Environmental Context	Hormonal Context	Workload Context	AVP™ Interpretation
Days 1–4	Fatigue, cramps, mild tachycardia, higher migraine risk	Stable AQI, but high indoor exposure from work	Menstruation	Moderate school stress	Avoid if flexible
Days 6–11	Sleep stable, HR closer to baseline, lower histamine symptoms	AQI green, no storm front, low mold/pollen alerts	Early-mid follicular	Predictable workdays	Best vaccination window
Days 13–16	Mild histamine symptoms, possible migraine sensitivity	AQI yellow from pollen rise	Ovulation	Higher student contact	Use caution
Days 19–25	Increased flushing, insomnia, tachycardia, migraine tendency	Storm front and humidity shift	Late luteal/progesterone drop	High workload	Delay if possible
Days 26–28	Fatigue rising, sleep worse, premenstrual MCAS pattern	Possible mold/pollen burden	Premenstrual	End-of-month workload	Avoid if flexible

Best modeled vaccination window: Days 6–11 of the month, assuming AQI remains green, there is no active mold exposure, no major storm front, no recent infection, and resting heart rate remains near baseline.

The point of the model is that her diagnosis does not change, but her readiness does. AVP™ shows that the safest window is not just “when she has time.” It is when immune terrain, hormones, environment, autonomic stability, and workload are all least likely to stack against recovery.

Post-Vaccination Recovery and Pacing Strategies

Post-vaccination recovery planning is equally important. Many immune-volatile patients report delayed crashes occurring 24 to 72 hours after exertion or immune stimulation rather than immediate symptoms. AVP™ therefore recommends proactive pacing, reduced exertional load, adequate sleep opportunity, hydration support, symptom monitoring, and avoidance of major physiologic stressors during the immediate post-vaccination period. Patients with ME/CFS and Long COVID may particularly benefit from avoiding overexertion during the recovery window because post-exertional malaise can amplify inflammatory and autonomic destabilization.

This is strongly aligned with ME/CFS guidance and pacing literature. NICE recognizes post-exertional symptom exacerbation as a defining feature of ME/CFS and recommends individualized energy management rather than fixed incremental exercise programs (NICE, 2021).

A 2023 scoping review of pacing in ME/CFS found that pacing is widely used to help patients manage limited energy and avoid post-exertional worsening, although implementation and evidence quality vary across studies (Sanal-Hayes et al., 2023). Patient-led Long COVID and ME/CFS clinical guidance also emphasizes planning for unavoidable exertion and reducing demands before and after predictable stressors.

Dynamic Terrain Variability in the Same Patient Across Time

Timepoint	Physiologic Context	Environmental Load	Hormonal State	Recovery Reserve	AVP™ Interpretation
Week 1	Stable sleep, controlled symptoms	AQI 22, no mold exposure	Mid-follicular	High	Green Window
Week 3	Poor sleep, mild PEM	AQI 68, high pollen	Ovulation	Moderate	Yellow Window
Week 5	Wildfire smoke exposure, tachycardia flare	AQI 132	Late luteal	Reduced	Orange/High Caution
Week 7	Recent viral exposure, severe fatigue, active migraine	Storm front + mold remediation	Menstruation	Low	Red Window

Conceptual Recovery Capacity Curve

Week 1 ─────────────── High Stability 

Week 3 ─────── Moderate Stability 

Week 5 ─── Significant Destabilization 

Week 7 ─ Critical Recovery Strain

This model demonstrates how the same patient may move between physiologic readiness states over time despite no change in underlying diagnosis. AVP™ therefore conceptualizes vaccine tolerance as a dynamic terrain-dependent variable influenced by cumulative inflammatory burden, environmental exposure, autonomic stability, hormonal state, and recovery reserve at the time of immune stimulation.

Monitoring, Wearables, and Flare Tracking

Monitoring within AVP™ extends beyond acute allergic reactions. The framework encourages short-term tracking of heart rate, blood pressure, temperature, oxygen saturation where appropriate, sleep disruption, neurologic symptoms, migraine activity, GI symptoms, mast cell symptoms, autonomic instability, and delayed flare behavior. Wearable data such as resting heart rate and HRV trends may provide additional insight into recovery trajectory, although these tools require further validation in vaccine-support settings.

The rationale for wearable-supported monitoring is growing. Long COVID research has shown altered heart rate variability and autonomic dysfunction in some patients, while newer wearable studies suggest that heart rate and HRV signals may help detect persistent physiologic changes after COVID-19 and potentially monitor autonomic dysfunction or overexertion patterns (Suh et al., 2023; Borhani et al., 2025; Ruijgt et al., 2025). This does not mean wearables can diagnose vaccine-related injury or replace clinical care. It means they may provide useful longitudinal context for patients whose destabilization is delayed, fluctuating, or autonomic in nature.

Preserving Access Through Adaptive Support

AVP™ ultimately emphasizes that adaptive support is intended to improve vaccine accessibility rather than reduce it. Many medically complex patients avoid vaccination not because they reject vaccines outright, but because they fear destabilization without adequate support or recognition. By integrating immune stabilization, environmental awareness, hormonal timing, autonomic accommodations, and structured monitoring into vaccine planning, AVP™ aims to strengthen public trust while preserving access to one of medicine’s most important preventive tools.

This positioning matters because infectious disease itself remains a major risk for immune-volatile patients. SARS-CoV-2 infection has been associated with cardiovascular complications, post-acute sequelae, dysautonomia, and long-term disability, and studies comparing post-vaccination POTS risk with post-infection POTS risk suggest that infection carries greater risk than vaccination (Xie et al., 2022; Davis et al., 2023; Kwan et al., 2022). AVP™ therefore occupies the responsible middle ground: preserve vaccine access, acknowledge rare and prolonged adverse experiences, and build adaptive safety infrastructure for patients whose physiology does not fit standard workflows.

Public Trust, Chronic Illness, and the Adaptive Safety Gap

Public trust surrounding vaccination has become increasingly polarized in recent years, particularly within chronically ill and disabled communities. Much of the current public discourse frames vaccine conversations through binary categories such as “pro-vaccine” versus “anti-vaccine,” leaving little room for nuanced discussion regarding immune volatility, individualized risk mitigation, or adaptive support for medically complex patients. As a result, many patients with Long COVID, ME/CFS, MCAS, dysautonomia, autoimmune disease, and environmentally reactive illnesses report feeling dismissed when describing prolonged flares, autonomic destabilization, or delayed symptom worsening following vaccination. This dynamic may contribute not only to declining trust in public health institutions, but also to reduced willingness among vulnerable populations to engage with future vaccination campaigns.

Historically, public health systems have focused appropriately on population-level safety outcomes, severe adverse event surveillance, and broad vaccine uptake. However, these systems are often less equipped to address chronic, delayed, fluctuating, or difficult-to-measure symptom trajectories that may occur in subsets of medically complex patients. Conventional surveillance systems such as VAERS were designed primarily as signal-detection tools rather than comprehensive chronic illness tracking systems (Shimabukuro et al., 2015). Patients with relapsing-remitting conditions may therefore experience a disconnect between their lived experiences and the narrow categories captured by existing safety frameworks. This disconnect becomes particularly problematic when patients already belong to populations historically excluded from research participation, disability recognition, or individualized care models.

Long COVID and related IACCs exposed many of these systemic weaknesses in real time. Millions of patients reported debilitating symptoms involving fatigue, post-exertional malaise, dysautonomia, neurologic dysfunction, mast cell activation, and inflammatory instability long before formal systems fully recognized these syndromes. Similar patterns have historically occurred in ME/CFS, dysautonomia, mast cell disorders, fibromyalgia, and women-dominated chronic illness populations, where patient reports often preceded large-scale institutional acknowledgment (Komaroff and Lipkin, 2021; Institute of Medicine, 2015). This history has shaped the context in which many immune-volatile patients now approach vaccination decisions.

Importantly, distrust does not necessarily equate to vaccine opposition. Many chronically ill patients actively seek vaccination while simultaneously fearing destabilization due to prior experiences with medications, infections, environmental exposures, or immune activation events.

In these cases, the problem is often not ideological resistance to vaccination itself, but rather the absence of adaptive support systems capable of addressing their physiologic complexity. Patients who fear severe flares may delay or avoid vaccination not because they reject immunization, but because they feel unsupported, unheard, or physiologically unprotected within current frameworks.

AVP™ attempts to address this adaptive safety gap by reframing vaccination support as a stabilization and monitoring process rather than a binary compliance decision. Within this model, clinicians acknowledge that medically complex patients may require individualized timing, environmental awareness, autonomic accommodations, mast cell stabilization strategies, and structured recovery planning. This approach may improve patient trust precisely because it validates physiologic complexity without abandoning evidence-based vaccination principles.

The framework also carries important equity implications. Women, disabled patients, environmentally ill patients, neuroimmune populations, and communities historically underrepresented in research may disproportionately experience the consequences of “one-size-fits-all” administration systems. Hormonal fluctuations, caregiving burden, occupational exposure, socioeconomic limitations, housing quality, mold exposure, air pollution burden, and reduced healthcare access may all influence physiologic stability and recovery capacity in ways that are rarely captured in standardized vaccine guidance. Adaptive frameworks such as AVP™ therefore represent not only a clinical innovation, but also a potential equity intervention for populations whose physiologic realities have historically remained underrecognized.

At the same time, AVP™ explicitly rejects fear-based framing and misinformation. The framework recognizes that SARS-CoV-2 infection itself carries substantial risks involving cardiovascular injury, autonomic dysfunction, neuroinflammation, thrombotic complications, disability, and chronic illness development (Xie et al., 2022; Davis et al., 2023). Research consistently demonstrates that the risk of severe COVID-related complications generally exceeds the risk of serious vaccine adverse events for most populations. AVP™ therefore does not position vaccination as uniquely dangerous. Instead, it proposes that medically vulnerable patients deserve safer administration infrastructure that reduces avoidable destabilization while preserving protection against infectious disease.

By acknowledging immune volatility without abandoning scientific rigor, AVP™ aims to create a more sustainable middle ground between institutional dismissal and fear-driven avoidance. In this model, trust is strengthened not through minimization of patient experiences, but through adaptive systems that recognize physiologic diversity and support individualized recovery needs.

Research Implications and Future Validation Pathways

The Adaptive Vaccination Protocol™ should be viewed as a hypothesis-generating and operational framework rather than a finalized clinical standard. Although many individual components of the framework are supported by existing literature involving mast cell biology, autonomic dysfunction, environmental inflammatory exposure, hormonal immune interaction, and vaccine adverse event monitoring, prospective validation studies evaluating these variables together in immune-volatile populations remain limited. AVP™ therefore represents an early systems-based attempt to operationalize multiple biologically plausible risk modifiers into a unified adaptive vaccine support model.

Prior CYNAERA modeling suggests that readiness-based vaccine support may have substantial prevention value when deployed across terrain-fragile populations. In The Uncounted: Vaccine Injury Prevalence, Economic Burden, and Reform, Va-IRI™ was modeled as a prevention framework designed to reduce avoidable injury risk by blocking vaccination during active infection, delaying vaccination during unstable terrain states, and applying enhanced support strategies for borderline readiness windows (Adinig, 2025). This prevention logic is consistent with the broader limitation of passive vaccine surveillance systems, including VAERS, which are useful for signal detection but are not designed to precisely estimate incidence, capture all events, or fully characterize delayed chronic illness trajectories (Shimabukuro et al., 2015; Miller et al., 2020; CDC, 2024; VAERS, 2025).

Using illustrative scenario assumptions, that model estimated that if 40 percent of chronic post-vaccination injuries arise in terrain-fragile cohorts targeted by Va-IRI™, and if readiness screening, deferral, stabilization, and adaptive dosing strategies reduced risk by 20 to 40 percent within that subgroup, approximately 800,400 to 1,600,800 injuries could be prevented (Adinig, 2025). At an estimated $25,000 annual societal cost per case, this would correspond to approximately $20.0 to $40.0 billion in annual savings. These estimates should be interpreted as scenario-based prevention modeling rather than confirmed prospective outcomes, but the economic assumptions are plausible when compared with adjacent chronic illness burden literature, including ME/CFS cost-of-illness studies, Long COVID labor-force impact estimates, and broader analyses showing that chronic post-infectious illness produces substantial direct medical, productivity, disability, and caregiver costs (Jason et al., 2008; Jason and Mirin, 2021; Cutler, 2022; Bach, 2022; OECD, 2026).

AVP™ extends this prevention logic by translating readiness assessment into operational administration steps. While Va-IRI™ identifies whether a patient may be in a red, yellow, or green readiness state, AVP™ addresses how to reduce avoidable destabilization through environmental timing, autonomic support, mast cell stabilization, hormonal awareness, pacing, and post-vaccination monitoring. This is especially relevant because Long COVID, ME/CFS, MCAS, dysautonomia, and related IACCs are associated with immune dysregulation, autonomic instability, post-exertional symptom exacerbation, environmental sensitivity, and impaired recovery after physiologic stressors (Komaroff and Lipkin, 2021; Klein et al., 2023; NICE, 2021; Sheldon et al., 2015; Sumantri et al., 2023).

The scalability of this approach is strengthened by the use of accessible clinical inputs. Va-IRI™ domains include commonly available measures such as CBC with differential, hs-CRP, ferritin, D-dimer, fibrinogen, antibody panels, symptom stability, and functional baseline, with optional specialty testing where available. This lowers deployment friction across public health systems, specialty clinics, federal programs, and research cohorts while preserving the need for prospective validation in Long COVID, post-vaccination syndrome, ME/CFS, MCAS, and dysautonomia populations. The implementation opportunity is therefore not only clinical but economic: even modest reductions in preventable destabilization could produce meaningful savings if concentrated among high-risk patients with costly chronic illness trajectories.

Several immediate research pathways emerge from this framework. First, prospective observational studies could evaluate whether vaccination timing relative to baseline symptom stability, environmental load, hormonal phase, or autonomic status influences short-term tolerability and flare outcomes in patients with Long COVID, MCAS, ME/CFS, dysautonomia, and related IACCs. Such studies could incorporate wearable metrics, symptom tracking, environmental exposure overlays, heart rate variability trends, inflammatory markers, and longitudinal recovery trajectories to identify patterns not captured by standard surveillance systems.

Environmental integration represents a particularly important future direction. Existing literature already supports links between PM2.5 exposure, wildfire smoke, mold exposure, inflammatory activation, asthma exacerbation, cardiovascular strain, and immune dysregulation (Rajagopalan et al., 2018; Rizzo et al., 2025). However, vaccine studies rarely account for concurrent environmental inflammatory burden despite its potential relevance to immune-volatile populations. Future AVP™ research could evaluate whether AQI levels, wildfire smoke exposure, mold burden, pollen counts, humidity, or storm-front pressure changes correlate with post-vaccination symptom severity or recovery duration in susceptible patients.

Hormonal timing also warrants targeted investigation. While evidence demonstrates interactions between sex hormones, mast cell activity, inflammatory signaling, and immune behavior (Zierau et al., 2012; Bonds and Midoro-Horiuti, 2013), few vaccine studies have examined whether menstrual cycle phase, perimenopause, hormone therapy, or endocrine instability influence tolerability or flare risk in chronically ill populations. Large cycle-tracking datasets and wearable technologies may provide future opportunities to evaluate these relationships at scale.

Wearable and digital biomarker integration could significantly expand adaptive monitoring capabilities. Heart rate variability, resting heart rate trends, sleep disruption, oxygen saturation, temperature changes, and autonomic instability markers may provide early indicators of post-vaccination physiologic stress in immune-volatile patients. AVP™ could therefore function as a foundation for future integration with systems such as SymCas™, VitalGuard™, wearable-linked monitoring platforms, and AI-assisted flare prediction tools capable of identifying destabilization patterns before severe crashes occur.

The framework may also have implications beyond vaccination alone. Many medically complex patients experience similar destabilization patterns following biologics, monoclonal antibodies, immune-modulating therapies, surgeries, anesthesia, endocrine treatments, or infectious exposures. As a result, AVP™ principles may ultimately contribute to broader adaptive administration models for immune-modulating interventions in vulnerable populations. This possibility becomes increasingly relevant as precision medicine, gene therapies, biologic therapies, and individualized immunologic interventions continue to expand.

Importantly, future AVP™ research must avoid overstating causation or encouraging unnecessary fear. Many symptoms reported after vaccination may overlap with preexisting chronic illness activity, background flare behavior, infection exposure, environmental triggers, or unrelated medical events. Prospective controlled studies will therefore be necessary to distinguish correlation from causation and identify which variables meaningfully affect tolerability or recovery outcomes. The goal of AVP™ is not to exaggerate vaccine risk, but to identify whether adaptive support strategies can improve safety, trust, recovery, and accessibility for medically vulnerable patients.

Emerging prevalence modeling further reinforces the urgency of adaptive vaccine-support infrastructure for medically vulnerable populations. In The Uncounted: Vaccine Injury Prevalence, Economic Burden, and Reform, CYNAERA modeling frameworks including US-CCUC™, VITAL™, S³, PULSE™, and IMPACT™ converged on an estimate that approximately 8–12 million Americans may be experiencing chronic health impacts following COVID-19 vaccination, with a substantial proportion involving neuroimmune, autonomic, mast-cell-mediated, and post-exertional phenotypes overlapping with infection-associated chronic conditions (Adinig, 2025).

Importantly, these projected phenotypes showed significant overlap with conditions already associated with immune volatility, including ME/CFS-like post-exertional illness, dysautonomia,

MCAS-hyperreactivity, autoimmune flare syndromes, neuropathic presentations, and chronic inflammatory instability. These findings suggest that future vaccine safety research may benefit from moving beyond binary adverse-event models toward terrain-informed frameworks capable of identifying biologic vulnerability before immune stimulation occurs. AVP™ was developed in part as a translational response to this challenge, operationalizing stabilization, environmental timing, autonomic support, mast cell awareness, and recovery monitoring into a unified adaptive administration framework for immune-fragile populations.

The framework also aligns with growing calls for expanded adverse-event surveillance windows and more sophisticated longitudinal monitoring systems. Prior CYNAERA modeling argued that conventional 7–28 day adverse-event tracking windows may fail to capture delayed-onset neuroimmune and autonomic flare patterns that emerge weeks to months after immune activation (Adinig, 2025). AVP™ therefore supports future integration with wearable biometrics, symptom-sequencing systems, environmental overlays, and longitudinal flare-tracking models capable of identifying recovery disruption in real time rather than relying exclusively on acute event capture.

Finally, AVP™ highlights the need for a broader shift toward terrain-informed medicine. Traditional models often treat interventions as static exposures delivered into interchangeable bodies. Immune-volatile illness challenges this assumption. Physiologic state, inflammatory burden, environmental exposure, autonomic capacity, endocrine status, and recovery reserve may all shape how a patient tolerates immune stimulation at a given moment. Future research capable of integrating these variables may ultimately improve not only vaccination outcomes, but the broader management of chronic inflammatory and neuroimmune disease.

Conclusion

The Adaptive Vaccination Protocol™ was developed to address a growing gap between conventional vaccine administration systems and the physiologic realities of immune-volatile chronic illness populations. Patients with Long COVID, ME/CFS, MCAS, dysautonomia, autoimmune disease, asthma, and environmentally reactive inflammatory conditions frequently experience nonlinear symptom behavior, autonomic instability, mast cell reactivity, delayed recovery, and heightened sensitivity to physiologic stressors. Yet current vaccine administration models rarely account for environmental inflammatory load, hormonal fluctuation, autonomic baseline, post-exertional vulnerability, or dynamic immune stability when planning vaccination in medically complex patients.

AVP™ proposes that vaccination in these populations may be safer and more tolerable when approached through an adaptive stabilization framework rather than a rigid calendar-based model. By integrating immune readiness assessment, mast cell stabilization, autonomic accommodations, environmental timing, hormonal awareness, and structured monitoring into vaccine planning, the framework seeks to reduce avoidable destabilization while preserving access to one of medicine’s most important preventive tools.

Importantly, AVP™ does not advocate vaccine avoidance. The framework explicitly recognizes that infectious diseases such as COVID-19 carry substantial risks involving cardiovascular injury, autonomic dysfunction, neuroinflammation, thrombosis, chronic disability, and death. Instead, AVP™ argues that medically vulnerable patients deserve administration systems that recognize physiologic diversity and provide individualized support when clinically appropriate. In this model, adaptive care becomes a mechanism for strengthening public trust rather than undermining it.

The framework also reflects a broader shift toward terrain-informed medicine. Immune stimulation does not occur in isolation. Vaccine tolerability may be shaped by inflammatory burden, autonomic reserve, endocrine state, environmental exposure, infection history, recovery capacity, and baseline physiologic stability. Although many aspects of AVP™ require prospective validation, the framework offers an early operational model for integrating these interacting variables into adaptive vaccine support systems for immune-volatile populations.

Ultimately, the goal of AVP™ is not to eliminate all risk, which is impossible in medicine. The goal is to reduce avoidable harm, improve recovery support, expand access for medically complex patients, and create a more nuanced, biologically informed approach to vaccination in the era of chronic immune-mediated disease.

Author Position on Vaccination

I am not anti-vaccine. I support vaccination as a core public health tool for preventing severe disease and death. My position is pro-safety, pro-accountability, and pro-readiness. This paper argues for modern guardrails that reduce avoidable harm in immune fragile populations: readiness scoring before dosing, clean excipient options, longer follow up windows, open safety data, and restoration of incentives for manufacturers to compete on safety. Safer design and smarter timing strengthen immunization programs and public trust, which ultimately increases vaccination uptake as a whole.

Frequently Asked Questions (FAQ)

Is AVP™ anti-vaccine?

No. AVP™ is an adaptive vaccine-support framework designed to improve safety, tolerability, monitoring, and recovery support for medically complex patients with immune volatility. The framework supports continued vaccine access while recognizing that some patients may require individualized stabilization strategies.

Who is AVP™ intended for?

AVP™ was designed primarily for patients with infection-associated chronic conditions and overlapping immune-volatile syndromes, including:

• Long COVID

• ME/CFS

• MCAS

• Dysautonomia/POTS

• Autoimmune disease

• Environmentally reactive inflammatory illness

• Severe post-viral syndromes

The framework may also have broader relevance for biologics, monoclonal antibodies, immune-modulating therapies, and future pandemic response systems.

Does AVP™ claim vaccines cause all chronic illnesses discussed in this paper?

No. AVP™ does not claim that all chronic illness symptoms following vaccination are caused by vaccination itself. Many symptoms overlap with preexisting conditions, post-viral syndromes, autoimmune disease, environmental triggers, or unrelated medical events. The framework instead argues that some patients may experience destabilization after immune stimulation and may benefit from adaptive support strategies.

Why does AVP™ focus on environmental exposures like wildfire smoke and mold?

Environmental exposures can increase inflammatory burden, autonomic strain, airway irritation, oxidative stress, and mast cell activation in susceptible individuals. AVP™ proposes that these exposures may reduce recovery reserve when layered onto immune stimulation in medically vulnerable patients.

Why does AVP™ include hormonal timing?

Hormones influence mast cell activity, immune signaling, autonomic regulation, migraine activity, and inflammatory response. Many patients with MCAS, dysautonomia, Long COVID, and autoimmune disease report predictable flare windows related to menstrual cycling, perimenopause, or endocrine instability. AVP™ incorporates these observations into adaptive timing considerations.

Does AVP™ recommend delaying vaccination?

Only in selected circumstances involving active instability or excessive cumulative physiologic burden. AVP™ is designed to support safer vaccination timing, not indefinite avoidance. Temporary deferral may be considered when clinically appropriate during severe flares, active infection, wildfire smoke exposure, major autonomic instability, or other destabilizing events.

Is there evidence supporting adaptive support strategies?

Many individual components of AVP™ are supported by existing literature involving mast cell disorders, dysautonomia management, environmental inflammatory exposure, post-exertional malaise, hormonal immune interaction, and vaccine safety monitoring. However, the integrated AVP™ framework itself remains hypothesis-generating and requires prospective validation.

How does AVP™ differ from standard vaccine guidance?

Conventional vaccine systems largely focus on contraindications and immediate adverse reactions. AVP™ additionally considers:

• Environmental inflammatory load

• Hormonal timing

• Autonomic stability

• Mast cell reactivity

• Delayed crash patterns

• Recovery reserve

• Trigger stacking

• Longitudinal monitoring

Does AVP™ replace physician guidance?

No. AVP™ is a research and systems framework intended to support individualized clinical decision-making, not replace licensed medical care or formal vaccination guidance.

What is the long-term goal of AVP™?

The long-term goal is to develop adaptive, terrain-informed vaccine-support systems that improve recovery, reduce avoidable destabilization, preserve public trust, and maintain vaccine access for medically vulnerable populations in future infectious disease and precision medicine settings.

CYNAERA Framework Papers and Core Research Libraries

This paper draws on a defined subset of CYNAERA Institute white papers that establish the methodological and analytical foundations of CYNAERA’s frameworks. These publications provide deeper context on prevalence reconstruction, remission, combination therapies and biomarker approaches. Our Long COVID Library,  ME/CFS Library, Lyme Library,  Autoimmune Library and CRISPR Remission Library are also in depth resources.

• Corrected National Prevalence Estimates for (IACCs)

• Therapeutic Polarity in Long COVID and ME/CFS

• Biological Adaptive Reduction State™ (BARS™)

• The Science of IACC Remission

• Primary Chronic Trigger (PCT)™ 

• CYNAERA Remission Standard™

• Aligned Intelligence Method (AIM™)

• The Hidden Public Health Cost of AI Data Centers

• Personalized CRISPR Remission™ for Autoimmune

• SymCas™: Symptom Flare Prediction in IACCs

• VitalGuard™ Environmental Flare Risk Engine

Author’s Note:

All insights, frameworks, and recommendations in this written material reflect the author's independent analysis and synthesis. References to researchers, clinicians, and advocacy organizations acknowledge their contributions to the field but do not imply endorsement of the specific frameworks, conclusions, or policy models proposed herein. This information is not medical guidance.

Patent-Pending Systems

Bioadaptive Systems Therapeutics™ (BST) and affiliated CYNAERA frameworks are protected under U.S. Provisional Patent Application No. 63/909,951. CYNAERA is built as modular intelligence infrastructure designed for licensing, integration, and strategic deployment across health, research, public sector, and enterprise environments.

Licensing and Integration

CYNAERA supports licensing of individual modules, bundled systems, and broader architecture layers. Current applications include research modernization, trial stabilization, diagnostic innovation, environmental forecasting, and population level modeling for complex chronic conditions. Basic licensing is available through CYNAERA Market, with additional pathways for pilot programs, institutional partnerships, and enterprise integration.

About the Author 

Cynthia Adinig is the founder of CYNAERA, a modular intelligence infrastructure company that transforms fragmented real world data into predictive insight across healthcare, climate, and public sector risk environments. Her work sits at the intersection of AI infrastructure, federal policy, and complex health system modeling, with a focus on helping institutions detect hidden costs, anticipate service demand, and strengthen planning in high uncertainty environments.

Cynthia has contributed to federal health and data modernization efforts spanning HHS, NIH, CDC, FDA, AHRQ, and NASEM, and has worked with congressional offices including Senator Tim Kaine, Senator Ed Markey,  Representative Don Beyer, and Representative Jack Bergman on legislative initiatives related to chronic illness surveillance, healthcare access, and data infrastructure. In 2025, she was appointed to advise the U.S. Department of Health and Human Services and has testified before Congress on healthcare data gaps and system level risk.

She is a PCORI Merit Reviewer, currently advises Selin Lab at UMass Chan, and has co-authored research  with Harlan Krumholz, MD, Akiko Iwasaki, PhD, and David Putrino, PhD, including through Yale’s LISTEN Study. She also advised Amy Proal, PhD’s research group at Mount Sinai through its CoRE advisory board and has worked with Dr. Peter Rowe of Johns Hopkins on national education and outreach focused on post-viral and autonomic illness. Her CRISPR Remission™ abstract was presented at CRISPRMED26 and she has authored a Milken Institute essay on artificial intelligence and healthcare.

Cynthia has been covered by outlets including TIME, Bloomberg, Fortune, and USA Today for her policy, advocacy, and public health work. Her perspective on complex chronic conditions is also informed by lived experience, which sharpened her commitment to reforming how chronic illness is understood, studied, and treated. She also advocates for domestic violence prevention and patient safety, bringing a trauma informed lens to her research, systems design, and policy work. Based in Northern Virginia, she brings more than a decade of experience in strategy, narrative design, and systems thinking to the development of cross sector intelligence infrastructure designed to reduce uncertainty, improve resilience, and support institutional decision making at scale.

References

1. Abrams, R.M.C., Simpson, D.M., Navis, A., Jette, N., Zhou, L. and Shin, S.C. 2020. ‘Small fiber neuropathy associated with SARS-CoV-2 infection’, Muscle & Nerve, 62(6), pp. E82–E84.

2. AAAAI. 2022. COVID-19 Vaccination & Mast Cell Activation Syndrome. American Academy of Allergy, Asthma & Immunology.

3. Adinig, C. 2025. The Uncounted: Vaccine Injury Prevalence, Economic Burden, and Reform. CYNAERA Research Frameworks.

4. Bhattacharjee, B. et al. 2025. ‘Immunological and antigenic signatures associated with chronic illness after COVID-19 vaccination’, medRxiv.

5. Bonadonna, P., Brockow, K., Niedoszytko, M., Elberink, H.O., Akin, C. and Nedoszytko, B. 2021. ‘COVID-19 vaccination in mastocytosis: Recommendations and safety considerations’, The Journal of Allergy and Clinical Immunology: In Practice, 9(6), pp. 2139–2144.

6. Bonds, R.S. and Midoro-Horiuti, T. 2013. ‘Estrogen effects in allergy and asthma’, Current Opinion in Allergy and Clinical Immunology, 13(1), pp. 92–99.

7. Borhani, S., Hutin, E., Muppidi, S., et al. 2025. ‘Wearable physiologic monitoring and autonomic dysfunction in Long COVID’, Frontiers in Digital Health, 7, pp. 1–14.

8. Bushi, A., Tzadok, S., Chorin, E., et al. 2024. ‘Autonomic dysfunction and postural orthostatic tachycardia syndrome after COVID-19 vaccination and infection’, Heart Rhythm O2, 5(1), pp. 41–49.

9. Cascio, W.E. 2018. ‘Wildland fire smoke and human health’, Science of the Total Environment, 624, pp. 586–595.

10. CDC. 2025. Coronavirus Disease 2019 (COVID-19) Vaccine Safety. Centers for Disease Control and Prevention.

11. CDC/NIOSH. 2025. Health Problems: Mold. National Institute for Occupational Safety and Health.

12. Cleveland Clinic. 2022. Postural Orthostatic Tachycardia Syndrome (POTS). Cleveland Clinic Health Library.

13. Davis, H.E., McCorkell, L., Vogel, J.M. and Topol, E.J. 2023. ‘Long COVID: major findings, mechanisms and recommendations’, Nature Reviews Microbiology, 21, pp. 133–146.

14. Denney, D.E., Matharu, M. and Goadsby, P.J. 2024. ‘Whether weather matters with migraine’, Headache, 64(2), pp. 145–158.

15. Edelman, A., Boniface, E.R., Benhar, E., et al. 2022. ‘Association between menstrual cycle length and coronavirus disease 2019 (COVID-19) vaccination’, Obstetrics & Gynecology, 139(4), pp. 481–489.

16. Gibson, E.A., Li, H., Check, J., et al. 2022. ‘COVID-19 vaccination and menstrual cycle length in the Apple Women’s Health Study’, NPJ Digital Medicine, 5(1), p. 165.

17. Greenhawt, M., Abrams, E.M., Shaker, M., et al. 2023. ‘Updated guidance regarding the risk of allergic reactions to COVID-19 vaccines and recommended evaluation and management’, Journal of Allergy and Clinical Immunology, 152(3), pp. 627–636.

18. Gutiérrez-Brito, J.A., Martínez-Cuazitl, A., Valencia-Mendoza, A., et al. 2025. ‘Sex hormones and allergies: exploring the gender difference in allergic disease’, Frontiers in Allergy, 6, pp. 1–15.

19. Harvard T.H. Chan School of Public Health. 2024. COVID-19 vaccines and menstrual cycles. Apple Women’s Health Study.

20. Institute of Medicine. 2015. Beyond Myalgic Encephalomyelitis/Chronic Fatigue Syndrome: Redefining an Illness. Washington, DC: National Academies Press.

21. Jin, Y., Chen, X., Podolsky, R., et al. 2019. ‘Fine particulate matter enhances FcεRI-mediated signaling and mast cell activation’, Toxicology Letters, 301, pp. 1–8.

22. Johns Hopkins Medicine. 2026. Postural Orthostatic Tachycardia Syndrome (POTS). Johns Hopkins Medicine.

23. Katsuki, M., Matsumori, Y., Kawamura, S., et al. 2023. ‘Investigating the effects of weather on headache occurrence’, Headache, 63(9), pp. 1203–1214.

24. Klein, J., Wood, J., Jaycox, J., et al. 2023. ‘Distinguishing features of Long COVID identified through immune profiling’, Nature, 623, pp. 139–148.

25. Komaroff, A.L. and Lipkin, W.I. 2021. ‘Insights from myalgic encephalomyelitis/chronic fatigue syndrome may help unravel the pathogenesis of postacute COVID-19 syndrome’, Trends in Molecular Medicine, 27(9), pp. 895–906.

26. Krumholz, H.M., Putrino, D., Iwasaki, A., et al. 2023. ‘Post-vaccination syndrome: a descriptive analysis of reported symptoms and patient experiences after COVID-19 immunization’, medRxiv.

27. Kwan, A.C., Ebinger, J.E., Botting, P., et al. 2022. ‘Apparent risks of postural orthostatic tachycardia syndrome diagnoses after COVID-19 vaccination and SARS-CoV-2 infection’, Nature Cardiovascular Research, 1, pp. 1187–1194.

28. Mendell, M.J., Mirer, A.G., Cheung, K., Tong, M. and Douwes, J. 2011. ‘Respiratory and allergic health effects of dampness, mold, and dampness-related agents’, Environmental Health Perspectives, 119(6), pp. 748–756.

29. National Academies of Sciences, Engineering, and Medicine. 2024. Evidence Review of the Adverse Effects of COVID-19 Vaccination and Intramuscular Vaccine Administration. Washington, DC: The National Academies Press.

30. NICE. 2021. Myalgic Encephalomyelitis (or Encephalopathy)/Chronic Fatigue Syndrome: Diagnosis and Management (NG206). National Institute for Health and Care Excellence.

31. Nicola, M., Varricchi, G., Marone, G. and Bonadonna, P. 2024. ‘Vaccination in mast cell disorders and mastocytosis’, Current Treatment Options in Allergy, 11(1), pp. 12–28.

32. Oaklander, A.L., Mills, A.J., Kelley, M., et al. 2022. ‘Peripheral neuropathy evaluations of patients with prolonged Long COVID’, Neurology: Neuroimmunology & Neuroinflammation, 9(3), e1146.

33. Pretorius, E., Vlok, M., Venter, C., et al. 2021. ‘Persistent clotting protein pathology in Long COVID/Post-Acute Sequelae of COVID-19 (PASC)’, Cardiovascular Diabetology, 20(172), pp. 1–18.

34. Rajagopalan, S., Al-Kindi, S.G. and Brook, R.D. 2018. ‘Air pollution and cardiovascular disease: JACC state-of-the-art review’, Journal of the American College of Cardiology, 72(17), pp. 2054–2070.

35. Rama, T.A., Moreira, A., Castells, M. and Matito, A. 2022. ‘COVID-19 vaccination is safe among mast cell disorder patients, under adequate premedication’, Vaccines, 10(2), p. 237.

36. Rizzo, L.V., Correia, C.A.S., Veiga, V.C., et al. 2025. ‘Wildfire smoke and health impacts: a narrative review’, Journal of Hazardous Materials, 472, 135149.

37. Ruijgt, G.S.M., Jackson, D., Betancourt, M.T., et al. 2025. ‘Wearable-derived physiologic trajectories in post-viral illness’, NPJ Digital Medicine, 8(1), pp. 1–13.

38. Sanal-Hayes, N.E.M., Baverel, P.G., Davey, A. and Smith, A.E. 2023. ‘Pacing as a strategy to manage post-exertional malaise in ME/CFS: a scoping review’, Journal of Translational Medicine, 21(1), p. 620.

39. Sheldon, R.S., Grubb, B.P., Olshansky, B., et al. 2015. ‘2015 heart rhythm society expert consensus statement on the diagnosis and treatment of postural tachycardia syndrome, inappropriate sinus tachycardia, and vasovagal syncope’, Heart Rhythm, 12(6), pp. e41–e63.

40. Shimabukuro, T.T., Nguyen, M., Martin, D. and DeStefano, F. 2015. ‘Safety monitoring in the Vaccine Adverse Event Reporting System (VAERS)’, Vaccine, 33(36), pp. 4398–4405.

41. Su, Y., Yuan, D., Chen, D.G., et al. 2022. ‘Multiple early factors anticipate post-acute COVID-19 sequelae’, Cell, 185(5), pp. 881–895.

42. Suh, S., Pierson, E., Rose, S., et al. 2023. ‘Heart rate variability and autonomic dysfunction in Long COVID using wearable devices’, PLOS Digital Health, 2(4), e0000224.

43. Sumantri, S., Kuswardhani, R.A.T. and Putra, I.B. 2023. ‘Immunological dysfunction and mast cell activation syndrome in Long COVID’, International Journal of Infectious Diseases, 130, pp. 104–113.

44. Tuazon, J.A., Zhao, Y., Castranova, V. and Ma, J.Y.C. 2022. ‘Emerging insights into the impact of air pollution on immune-mediated asthma’, Frontiers in Immunology, 13, 930810.

45. Wang, E.Y., Mao, T., Klein, J., et al. 2021. ‘Diverse functional autoantibodies in patients with COVID-19’, Nature, 595, pp. 283–288.

46. Wang, Q., Xue, Y., Zhang, Y., et al. 2021. ‘PM2.5 exposure promotes mast cell activation and systemic inflammation’, Environmental Pollution, 268, 115892.

47. Xie, Y., Choi, T. and Al-Aly, Z. 2022. ‘Long-term cardiovascular outcomes of COVID-19’, Nature Medicine, 28, pp. 583–590.

48. Yong, S.J. 2023. ‘Pooled rates and demographics of POTS following SARS-CoV-2 infection versus COVID-19 vaccination’, Autonomic Neuroscience, 250, 103143.

49. Zierau, O., Zenclussen, A.C. and Jensen, F. 2012. ‘Role of female sex hormones, estradiol and progesterone, in mast cell behavior’, Frontiers in Immunology, 3, p. 169.